RUNX1 and acute myeloid leukemia: In a 2021 study by Waidhauser et al. [16], the median age of AML patients with RUNX1+ was 57.4 years, and 2-year OS and LFS after transplantation was 66.6% (95% CI: 62.4–70.8) and 61% (95% CI: 62.4-70.8).